Patents by Inventor Rex Parker

Rex Parker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fibronectin based scaffold domain proteins that bind PCSK9
    Patent number: 11858979
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: January 2, 2024
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20220204589
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: November 16, 2021
    Publication date: June 30, 2022
    Inventors: Tracy S. MITCHELL, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan H. Davis, David Fabrizio
  • Serum albumin-binding fibronectin type III domains
    Patent number: 11203630
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: December 21, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan H. Davis, David Fabrizio
  • FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9
    Publication number: 20210277089
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Application
    Filed: February 16, 2021
    Publication date: September 9, 2021
    Inventors: Ray CAMPHAUSEN, Jonathan H. DAVIS, Sharon T. CLOAD, Fabienne M. DENHEZ, Amna SAEED-KOTHE, Dasa LIPOVSEK, Ching-Hsiung Frederick LO, Chee Meng LOW, Bowman MIAO, Tracy S. MITCHELL, Rex A. PARKER, Ginger C. RAKESTRAW, Katie A. RUSSO, Doree F. SITKOFF
  • Fibronectin based scaffold domain proteins that bind PCSK9
    Patent number: 10947297
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: March 16, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20200048328
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: August 23, 2019
    Publication date: February 13, 2020
    Inventors: Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Rex PARKER, Ray CAMPHAUSEN, Jonathan DAVIS, David FABRIZIO
  • Serum albumin-binding fibronectin type III domains
    Patent number: 10442851
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: October 15, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan Davis, David Fabrizio
  • FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9
    Publication number: 20180201665
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Application
    Filed: November 21, 2017
    Publication date: July 19, 2018
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • Fibronectin based scaffold domain proteins that bind PCSK9
    Patent number: 9856309
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: January 2, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20170174748
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: March 19, 2015
    Publication date: June 22, 2017
    Inventors: Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Rex PARKER, Ray CAMPHAUSEN, Jonathan DAVIS, David FABRIZIO
  • FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9
    Publication number: 20160159883
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Application
    Filed: December 2, 2015
    Publication date: June 9, 2016
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • Fibronectin based scaffold domain proteins that bind PCSK9
    Patent number: 9234027
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 12, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • Fibronectin based scaffold domain proteins that bind to PCSK9
    Patent number: 8420098
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: April 16, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO PCSK9
    Publication number: 20120094909
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Application
    Filed: April 13, 2011
    Publication date: April 19, 2012
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • Method for treating atherosclerosis employing an aP2 inhibitor and combination
    Publication number: 20090076033
    Abstract: A method is provided for treating atherosclerosis and related diseases, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antiatheroscletotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin.
    Type: Application
    Filed: April 15, 2008
    Publication date: March 19, 2009
    Inventors: Jeffrey A. Robl, Rex A. Parker, Scott A. Biller, Haris Jamil, Bruce L. Jacobson, Krishna Kodukula, Gokhan Hotamisligil
  • Method for treating diabetes employing an aP2 inhibitor and combination
    Patent number: 7390824
    Abstract: A method is provided for treating diabetes and related diseases, especially Type II diabetes, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: June 24, 2008
    Assignees: Bristol-Myers Squibb Company, Pesident and Fellows of Harvard College
    Inventors: Jeffrey A. Robl, Rex A. Parker, Scott A. Biller, Haris Jamil, Bruce L. Jacobson, Krishna Kodukula
  • Method for treating atherosclerosis employing an aP2 inhibitor and combination
    Patent number: 7358254
    Abstract: A method is provided for treating atherosclerosis and related diseases, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antiatherosclerotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin.
    Type: Grant
    Filed: June 21, 2004
    Date of Patent: April 15, 2008
    Assignees: Bristol-Myers Squibb Company, President & Fellows of Harvard College
    Inventors: Jeffrey A. Robl, Rex A. Parker, Scott A. Biller, Haris Jamil, Bruce L. Jacobson, Krishna Kodukula, Gokhan Hotamisligil
  • Polynucleotides encoding novel PCSK9 variants
    Publication number: 20080008697
    Abstract: The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Application
    Filed: June 28, 2007
    Publication date: January 10, 2008
    Inventors: Gabriel Mintier, Jian Chen, John Feder, Bowman Miao, Rex Parker
  • Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
    Patent number: 6984645
    Abstract: Compounds that are dual aP2/k-FABP inhibitors are provided having the formula wherein A, B, X, Y, R1, R2 and R3 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing dual aP2/k-FABP inhibitors alone or in combination with at least one other antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: January 10, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: David R. Magnin, Richard B. Sulsky, Jeffrey A. Robl, Thomas J. Caulfield, Rex A. Parker
  • Method for treating atherosclerosis employing an aP2 inhibitor and combination
    Publication number: 20040229807
    Abstract: A method is provided for treating atherosclerosis and related diseases, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antiatherosclerotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin.
    Type: Application
    Filed: June 21, 2004
    Publication date: November 18, 2004
    Inventors: Jeffrey A. Robl, Rex A. Parker, Scott A. Biller, Haris Jamil, Bruce L. Jacobson, Krishna Kodukula